In a recent column published on Specialty Pharmacy Times, National Pharmaceutical Council President and CEO Dan Leonard says the international pricing index proposed by the Centers for Medicare and Medicaid Services (CMS) would “undermine” the agency’s “goal of prioritizing value and improved patient outcomes over utilization and sickness.”
“The IPI model, as outlined, has critical methodological limitations that would have numerous adverse consequences, leading to restrictions in health care innovation and impeding patient access to needed health care services and products,” Leonard writes.
There exist three key concerns, he writes:
- Economic differences between countries tapped for international index;
- Global index would hamper incentives for biopharmaceutical innovation; and
- Policies targeting high health costs should be broad in scope of services.
To read Leonard’s full column on Specialty Pharmacy Times, click here.